A global leader in influenza prevention announced that the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Administration for Strategic Preparedness and Response, had selected CSL Seqirus to manufacture and clinically assess a cell-based, adjuvanted pre-pandemic influenza vaccine candidate to support the U.S. government's pandemic preparedness activities.
$30 Million Awarded for Another Bird Flu Vaccine Candidate
A global leader in influenza prevention announced that the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Administration for Strategic Preparedness and Response, had selected CSL Seqirus to manufacture and clinically assess a cell-based, adjuvanted pre-pandemic influenza vaccine candidate to support the U.S. government's pandemic preparedness activities.
Pollution Tied to Risk for Serious COVID-19 Despite Vaccination
Exposures to PM2.5 and NO2 linked to increased risk for COVID-19-related hospitalization, with and without adjustment for vaccination
SARS-CoV-2 May Not Cause Increase in Type 1 Diabetes in Children
For children aged 0 to 14 years, incidence of type 1 diabetes was 20 percent higher in 2020 to 2021 than the seven-year average